dual agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
== Moving wire IRMS == Moving wire IRMS is useful for analyzing carbon-13 ratios of compounds in a solution, such as after purification by liquid chromatography. The solution (or outflow from the chromatography) is dried onto a nickel or stainless steel wire. After the residue is deposited on the wire, it enters a furnace where the sample is converted to CO2 and water by combustion. The gas stream finally enters a capillary, is dried, ionized, and analyzed. This process allows a mixture of compounds to be purified and analyzed continuously, which can decrease the analysis time by a factor of four. Moving wire IRMS is quite sensitive, and samples containing as little as 1 nanomole of carbon can yield precise (within 1‰) results.
==== Gas cycle ==== In a gas refrigeration cycle, the working fluid remains gaseous while it is compressed and expanded; unlike a vapor-compression cycle, it does not undergo condensation and evaporation. Air is commonly used as the working fluid in air-cycle refrigeration. In a basic air cycle, air is compressed, cooled in a heat exchanger, expanded to reduce its temperature, and then absorbs heat from the space or system being cooled. Air-cycle refrigeration is based on the reverse Brayton cycle. In aircraft systems, compressed air is cooled in a heat exchanger and then expanded through a turbine to produce refrigerated air. Reverse-Brayton air refrigeration generally has a lower coefficient of performance than conventional vapor-compression refrigeration, although its low mass, compactness and reliability make it suitable for aircraft environmental-control applications. Air-cycle refrigeration is the predominant method of air conditioning in commercial and military aircraft. In conventional bleed-air systems, air supplied from a gas-turbine engine compressor is cooled and expanded in an air cycle machine before being supplied to the aircraft environmental-control system. Air-cycle machines typically combine a turbine with a compressor, fan, or both. Some newer aircraft instead use electrically powered bleedless air-cycle systems.
=== Lidar eye-tracking in LASIK === In the 1980s, NASA developed LADAR (for Laser RADAR, now more commonly called Lidar) technology for autonomous rendezvous and docking of space vehicles to service satellites. LASIK surgeons of the time happened to have a problem: patients make involuntary eye movements as frequently as 100 times per second, so the LASIK machine must follow the eye movement to accurately reshape the cornea, the clear front surface of the eye, using a laser. Existing video trackers were too slow, causing interruptions when tracking is lost. The LADARVision 4000, approved in 1998, automatically tracks eye movements at a rate of 4,000 times per second while reshaping the cornea. Lidar is also used in military and NASA-sponsored research for applications in strategic target tracking and weapons firing control.
Collision avoidance system – a short range radar or LIDAR system on an automobile or vehicle that detects if the vehicle is about to collide with an object and applies the brakes to prevent the collision. Radar fuze – a detonator for an aerial bomb which uses a radar altimeter to measure the height of the bomb above the ground as it falls and detonates it at a certain altitude.
Sources: en.wikipedia.org
Nayib Armando Bukele Ortez (born 24 July 1981) is a Salvadoran politician who has served as the 43rd president of El Salvador since 2019. In 1999, Bukele established an advertising company and worked at another owned by his father, Armando Bukele Kattán. Both companies advertised election campaigns for the Farabundo Martí National Liberation Front (FMLN) political party. Bukele entered politics in 2011. In 2012, he joined the FMLN and was elected mayor of Nuevo Cuscatlán. Bukele served until his 2015 election as Mayor of San Salvador, where he served until 2018. In 2017, Bukele was ousted from the FMLN. He founded the Nuevas Ideas political party shortly afterward and pursued a presidential campaign in 2019. After the Supreme Electoral Court (TSE) refused to register his party, Bukele ran for president with the Grand Alliance for National Unity (GANA) and won with 53 percent of the vote. In July 2019, Bukele implemented the Territorial Control Plan to reduce El Salvador's 2019 homicide rate of 38 per 100,000 people. Homicides fell by 50 percent during Bukele's first year in office. After 87 people were killed by gangs over one weekend in March 2022, Bukele initiated a nationwide crackdown on gangs, resulting in the arrests of over 85,000 people with alleged gang affiliations by December 2024. El Salvador's homicide rate officially decreased to 1.9 homicides per 100,000 in 2024, one of the lowest in the Americas, although the factual accuracy has been contested.
On 1 October, the Israeli military began an invasion of southern Lebanon, also known as the Third Lebanon War by some Israeli sources, and announced that Israel had been carrying out small covert raids into Lebanon for months. The IDF announced that it had launched "limited, localized and targeted raids" against targets with strategic importance to Hezbollah. An Israeli strike on a house in Al-Dawoudiya killed at least 10 people and injured five others. Hours after the initial Israeli raids began, Iran launched ballistic missiles against Israel, citing "terrorist acts of the Zionist regime" such as the assassination of Hassan Nasrallah as justification for the attack. On 3 October, six days after Nasrallah's assassination, his successor, Hashem Safieddine, was also assassinated during an Israeli airstrike in Beirut. Israel kept the extent of its campaign vague. On 29 October, IDF officers said that while some Lebanese villages still pose a threat to Israel, most military goals in Lebanon border area were fulfilled and conditions were created to cement Israel's achievements in ceasefire negotiations. On 26 November, hours after IDF troops reached the Litani River, Prime Minister of Israel Benjamin Netanyahu announced the transfer of a sixty-day ceasefire deal to the Security Cabinet of Israel. Support for the deal in the Israeli government was "unanimous". The deal involved Hezbollah operatives withdrawing to the north of the Litani River, and Israel withdrawing from Lebanon at the end of the sixty days.
The time frame in question when dealing with radioactive waste ranges from 10,000 to 1,000,000 years, according to studies based on the effect of estimated radiation doses. Researchers suggest that forecasts of health detriment for such periods should be examined critically. Practical studies only consider up to 100 years as far as effective planning and cost evaluations are concerned. Long term behavior of radioactive wastes remains a subject for ongoing research projects in geoforecasting.
Sources: en.wikipedia.org
We hold the truth that all men are created equal, that they are endowed by their Creator with certain unalienable rights, among them life, liberty and the pursuit of happiness. Ho Chi Minh denounced the reimposition of French rule, accusing the French of selling out the Vietnamese to the Japanese twice in four years.
=== Temperature === Temperature is another interesting parameter to discuss since protein solubility is a function of temperature. In protein crystallization, manipulation of temperature to yield successful crystals is one common strategy. Unlike pH, temperature of different components of the crystallography experiments could impact the final results such as temperature of buffer preparation, temperature of the actual crystallization experiment, etc.
=== Growth hormone receptor mutations === Molecular genetic investigations have shown that LS is mainly associated with autosomal recessive mutations in the gene for the growth hormone receptor (GHR). These can result in defective hormone binding to the ectodomain or reduced efficiency of dimerization of the receptor after hormone occupancy. LS is generally classified as "primary" GH insensitivity, which is distinguished from "secondary" GH insensitivity. Primary (congenital/hereditary) GH insensitivity may result from growth hormone receptor defects, as in the case of Laron syndrome, but can also be caused by defective post-receptor signal transduction (STAT5B), abnormalities of the IGF-1 gene or IGF-1 receptor. Secondary (acquired) GH insensitivity results from antibodies to growth hormone or the growth hormone receptor, as well as poor nutritional status, liver disease or diabetes mellitus. A GHR mutation that results in only partial insensitivity to GH can manifest as a form of idiopathic short stature.
On 12 November 1935 at the Hospital de Santa Marta in Lisbon, Moniz initiated the first of a series of operations on the brains of people with mental illnesses. The initial patients selected for the operation were provided by the medical director of Lisbon's Miguel Bombarda Mental Hospital, José de Matos Sobral Cid. As Moniz lacked training in neurosurgery and his hands were impaired by gout, the procedure was performed under general anaesthetic by Pedro Almeida Lima, who had previously assisted Moniz with his research on cerebral angiography. The intention was to remove some of the long fibres that connected the frontal lobes to other major brain centres. To this end, it was decided that Lima would trephine into the side of the skull and then inject ethanol into the "subcortical white matter of the prefrontal area" so as to destroy the connecting fibres, or association tracts, and create what Moniz termed a "frontal barrier". After the first operation was complete, Moniz considered it a success and, observing that the patient's depression had been relieved, he declared her "cured" although she was never, in fact, discharged from the mental hospital. Moniz and Lima persisted with this method of injecting alcohol into the frontal lobes for the next seven patients, but, after having to inject some patients on numerous occasions to elicit what they considered a favourable result, they modified the means by which they would section the frontal lobes.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.